Statement on Open Science and Open Praxis with Psilocybin, MDMA, and Similar Substances

As an expert group in the field of research and development of psychedelic medicine, Beyond Psychedelis had also signed the below document and we follow these standards and commitments in the Beyond Psychedelics conference.



The undersigned individuals and organizations work to advance the understanding and beneficial uses of substances called (among many names) psychedelics, hallucinogens, or entheogens. Our fields include medicine and traditional healing, medicinal chemistry and ethnopharmacology, psychopharmacology, neuroscience, psychology, counseling, religion, public health, and public policy.

From generations of practitioners and researchers before us, we have received knowledge about these substances, their risks, and ways to use them constructively. In turn, we accept the call to use that knowledge for the common good and to share freely whatever related knowledge we may discover or develop.

Therefore, in this work, we commit to the following principles. If we engage with consultants, contractors, or suppliers, we will do so in ways that uphold these principles.

1. Intellectual and scientific integrity. We affirm that we report the truth as we find it, not as we or others might prefer it to be found. We will present disappointing or adverse results as well as affirming or encouraging ones. We will properly attribute the contributions of others.

2. In service. While we may need to be paid for our labor, we are called to this work in the spirit of service. We will place the common good above private gain, and we will work for the welfare of the individuals and communities served. We will strive to make our expertise and services available to all who may benefit from them, even those whose means are limited.

3. Open science and open praxis. We will not withhold, nor will we require others to withhold, materials or knowledge (experiences, observations, discoveries, methods, best practices, or the like) for commercial advantage. This does not preclude the appropriate management of raw data or the exercise of data exclusivity rights, but we will make those decisions for the common good rather than for private gain. Nor does this preclude reasonable and ordinary charges for our books, other media, software, materials, or professional services.

4. Non-interference. We will strive to place our discoveries into the public domain, for the benefit of all. If we have patents or patents pending, we will license that intellectual property, for no more than reasonable and ordinary administrative costs, to anyone who will use it for the common good and in alignment with these principles.

Signatories may refine or expand their commitments, broadly in keeping with these principles, via further public statements. This document is an evolving work, with signatures being added. They are provisional pending a final release.

Clerk: Robert Jesse. Please email if you’d like yourself or your organization to be included.

The latest version of this document and signatories list can be found at

Poslední příspěvky


Za hranice vědomí se Stanislavem Grofem

Těžko bychom dnes hledali člověka s rozsáhlejšími znalostmi a zkušenostmi z oblasti rozšířených stavů vědomí, známých také jako stavy změněné, holotropní či psychedelické. Stavy, které


Cesta psychonauta. Česká premiéra v kinech

Zveme na film o životě a díle jednoho z nejvýznamnějších průkopníků psychedelické terapie se zkušenostmi z více než 4500 LSD sezení, spoluzakladatele transpersonální psychologie a